热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
Brilliant Violet 650™ anti-mouse/human CD11b
产品名称：
Brilliant Violet 650™ anti-mouse/human CD11b
产品类别：
抗体
产品编号：
101239
产品应用：
101239
[价格]
规格 价格 库存
125µL ￥ 2508 1

产品详情

Product Details

Verified Reactivity
Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Rabbit
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C57BL/10 splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 650? under optimal conditions.
Concentration
?g size: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤0.3 ?g per million cells in 100 ?l volume. For flow cytometric staining using the test size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 650? excites at 405 nm and emits at 645 nm. The bandpass filter 660/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 650? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone M1/70 has been verified for?immunocytochemistry (ICC) and frozen immunohistochemistry (IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1,4, in vitro blocking3,9,12, depletion2,8, immunofluorescence microscopy6,7,10, immunohistochemistry of acetone-fixed frozen sections5,11-13, and spatial biology (IBEX)35,36. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) (Cat. No. 101248).

Application References

(PubMed link indicates BioLegend citation)
  1. Springer T, et al. 1978. Eur. J. Immunol. 8:539. (IP)
  2. Ault K and Springer T. 1981. J. Immunol. 126:359. (Deplete)
  3. Springer TA, et al. 1982. Immunol. Rev. 68:171. (Block)
  4. Ho MK and Springer TA. 1983. J. Biol. Chem. 258:2766. (IP)
  5. Flotte TJ, et al. 1983. Am. J. Pathol. 111:112. (IHC)
  6. Noel GJ, et al. 1990. J. Clin. Invest. 85:208. (IF)
  7. Allen LA and Aderem A. 1996. J. Exp. Med. 184:627 (IF)
  8. D'Amico A and Wu L. 2003. J. Exp. Med. 198:293. (Deplete)
  9. Brickson SJ, et al. 2003. Appl Physiol. 95:969. (Block)
  10. Clatworthy MR and Smith KG. 2004. J. Exp. Med. 199:717. (IF)
  11. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  12. Zhang Y, et al. 2002. J. Immunol. 168:3088. (IHC)
  13. Iwasaki A and Kelsall BL. 2001. J. Immunol. 166:4884 (IHC, FC)
  14. Tailleux L. 2003. J. Exp. Med. 197:121. (Block, FC)
  15. Olver S, et al. 2006. Cancer Research 66:571. (FC)
  16. Tan SL, et al. 2006. J. Immunol. 176:2872. (FC) PubMed
  17. Ponomarev ED, et al. 2006. J. Immunol. 176:1402. (FC)
  18. Dzhagalov I, et al. 2007. Blood 109:1620. (FC)
  19. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  20. Rasmussen JW, et al. 2006. Infect. Immun.74:6590. PubMed
  21. Napimoga MH, et al. 2008. J. Immunol. 180:609. PubMed
  22. Elqaraz-Carmon V, et al. 2008. J. Lipid. Res. 49:1894. PubMed
  23. Kim DD, et al. 2008. Blood 112:1109. PubMed
  24. Guo Y, et al. 2008. Blood 112:480. PubMed
  25. Norian LA, et al. 2009. Cancer Res. 69:3086. (FC) PubMed
  26. Baumgartner CK, et al. 2010. J. Immunol. 184:573. PubMed
  27. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  28. Whiteland J, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
  29. Weber GF, et al. 2014. J Exp Med. 211:1243. PubMed
  30. Ashok A, et al. 2015. Toxicol Sci. 143:64. PubMed
  31. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  32. Doni A, et al. 2015. J Exp Med. 212:905. PubMed
  33. Ferreira R, et al. 2016. J Infect Dis. 213: 669 - 673. PubMed
  34. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  35. Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
  36. Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
Product Citations
  1. ?zcan A, et al. 2020. J Invest Dermatol. 1003:140. PubMed
  2. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  3. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  4. Sierro F, et al. 2017. Immunity. 47:374. PubMed
  5. Sch?nberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  6. Hulsebus HJ, et al. 2022. Front Immunol. 13:884719. PubMed
  7. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  8. Grubman A, et al. 2020. Stem Cell Reports. 1.290277778. PubMed
  9. Matsushita Y, et al. 2021. J Bone Miner Res. 36:1145. PubMed
  10. Blecher-Gonen R, et al. 2019. Cell Syst. 8:109. PubMed
  11. Gimblet C et al. 2017. Cell host & microbe. 22(1):13-24 . PubMed
  12. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
  13. Lechner AJ et al. 2017. Cell stem cell. 21(1):120-134 . PubMed
  14. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  15. Brestoff JR, et al. 2021. Cell Metab. 33:270. PubMed
  16. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  17. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  18. Lees JG, et al. 2020. PLoS One. 15:e0238164. PubMed
  19. Bagayoko S, et al. 2021. PLoS Pathog. 17:e1009927. PubMed
  20. Tuit S, et al. 2019. Cell Rep. 29:1221. PubMed
  21. Li H, et al. 2019. Cell. 176:775. PubMed
  22. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  23. Wiesner D, et al. 2015. PLoS Pathog. 11:1004701. PubMed
  24. Thion MS et al. 2018. Cell. 172(3):500-516 . PubMed
  25. Bittner–Eddy PD, et al. 2017. Front Immunol. 1.304166667. PubMed
  26. Uceda-Castro R, et al. 2022. Cell Rep Med. 3:100821. PubMed
  27. Chakraborty S, et al. 2022. Sci Transl Med. . PubMed
  28. Benechet AP, et al. 2019. Nature. 574:200. PubMed
  29. Costa A et al. 2018. Cancer cell. 33(3):463-479 . PubMed
  30. Warheit-Niemi HI, et al. 2022. JCI Insight. 7:. PubMed
  31. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  32. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  33. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  34. Marn Franco JL, et al. 2020. Cell Reports. 33(13):108547. PubMed
  35. BenYoucef A, et al. 2020. J Allergy Clin Immunol. 145:1690. PubMed
  36. Gniadek TJ, et al. 2020. J Immunother. 43:217. PubMed
  37. Tritz ZP, et al. 2020. J Immunol. 205:1228. PubMed
  38. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  39. De Simone G, et al. 2021. Immunity. :. PubMed
  40. Li Y, et al. 2020. Cell Reports. 27(10):2809-2816.e3.. PubMed
  41. Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed
  42. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  43. Blriot C, et al. 2021. Immunity. :. PubMed
  44. Shreeve N, et al. 2021. Immunity. 54(6):1231-1244.e4. PubMed
  45. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  46. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  47. Stifter SA, et al. 2019. Cell Rep. 29:3539. PubMed
  48. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  49. Colliou N, et al. 2015. Toxins. 7: 3805 - 3817. PubMed
  50. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  51. Su W et al. 2019. Cancer Cell. 36(2):139-155 . PubMed
  52. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  53. Abdelfattah N, et al. 2022. Nat Commun. 13:767. PubMed
  54. Riedel R, et al. 2020. Nat Commun. 11:2570. PubMed
  55. Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed
  56. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  57. Shen XR, et al. 2021. Viruses. 13:. PubMed
  58. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  59. Evrard M et al. 2018. Immunity. 48(2):364-379 . PubMed
  60. Teo TH, et al. 2018. Nat Commun. 9:3905. PubMed
  61. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  62. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  63. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  64. Moreno M et al. 2014. The Journal of Neuroscience. 34(24):8175-85 . PubMed
  65. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  66. Lee A, et al. 2022. Nat Commun. 13:549. PubMed
  67. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  68. Zhu Y et al. 2017. The Journal of Neuroscience. 37(9):2362-2376 . PubMed
  69. O'Boyle C, et al. 2020. Int J Stroke. 0.746527778. PubMed
  70. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  71. Terlizzi M, et al. 2021. Cell Physiol Biochem. 55:539. PubMed
  72. Andreata F, et al. 2021. STAR Protoc. 2:100831. PubMed
  73. Yu YR, et al. 2020. STAR Protocols. 11(3):e0150606. PubMed
RRID
AB_11125575 (BioLegend Cat. No. 101239) AB_2566568 (BioLegend Cat. No. 101259)

Antigen Details

Structure
Integrin family, associates with integrin β2 (CD18), 170 kD
Distribution

Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells

Function
Adhesion, chemotaxis
Ligand/Receptor
ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type
B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Springer TA. 1994. Cell 76:301.
3. Coxon A, et al. 1996. Immunity 5:653.

Gene ID
16409 View all products for this Gene ID 3684 View all products for this Gene ID
UniProt
View information about CD11b on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线